Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Raman Active, Smart Diatom Frustules as Next Generation Multimodal Theranostics for Safe and Superior Colorectal Cancer Treatment

Project description

Smart nanotheranostics for colorectal cancer

Current treatments for colorectal cancer including chemotherapy, radiation, and surgery are non-specific and cause substantial side effects. This highlights the urgent need for safer and more effective strategies. With the support of the Marie Skłodowska-Curie Actions programme, the DIASHUTTLE project aims to develop a multifunctional nanotheranostic platform that combines magnetic and gold nanoparticles, tumour-targeting folic acid, and the natural compound astaxanthin. This novel approach aims to simultaneously achieve targeted drug delivery, magnetic hyperthermia, and photothermal therapy. It will also facilitate real-time monitoring through imaging and spectroscopy. DIASHUTTLE promises enhanced anti-cancer efficacy and reduced toxicity.

Objective

Colorectal cancer accounted for 12.7% of all new cancer diagnosis and 12.4% of all deaths due to cancer in European Union in 2020. Despite the advances in therapeutics, it is the most recurrent tumors in humans and third common cause of cancer-related deaths worldwide. The current treatment options include chemotherapy, radiation and surgery that are invasive and have side-effects. Also, the 1st and 2nd generation nanocarriers used in cancer therapy consisted of mono-component systems and failed due to lack of targeting molecules, remotely controlled therapeutics window, and patient-specific individualized platforms. The project DIASHUTTLE aims to develop a novel, next-generation, smart, multifunctional and multimodal, hybrid nanotheranostic platform consisting of biosilica extracted from living diatoms for simultaneous diagnosis, treatment, and therapy monitoring of colorectal cancer. It will combine magnetic nanoparticle core, surface deposited metallic gold nanoparticles, tumor targeting biomolecule folic acid, and natural source drug astaxanthin to facilitate different modes of therapy such as magnetically guided or ligand targeted drug delivery, magnetic hyperthermia, and photothermal therapy. It will also concurrently enable different modes of real-time monitoring such as Raman, surface enhanced Raman spectroscopy, magnetic resonance imaging, fluorescence, and photoluminescence. It is expected that the combination of different therapies will exhibit superior synergistic anti-cancer effect over monotherapy and reduce treatment delays by offering a safe and personalized approach to overcome the limitations of conventional cancer treatment. The proposed platform will lead to less toxicity due to the use of targeting molecule and natural materials, controlled drug release, and lower effective drug concentration. Additionally, the nutrient uptake and CO2 sequestration capability of diatoms will support circular bio-economy and self-sustainability.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2022-PF-01

See all projects funded under this call

Coordinator

CONSIGLIO NAZIONALE DELLE RICERCHE
Net EU contribution
€ 235 737,60
Address
PIAZZALE ALDO MORO 7
00185 Roma
Italy
Region
Centro (IT) Lazio Roma
Activity type
Research Organisations
Links
Total cost
No data

Partners (1)